Genmab — Februar 2019

bibob

Det ligner samme mønster som sædvanlig. Kør kursen op , og tag gevinsten til luk. Nothing changes so far.

JKY_VH

lad os nu se om ikke mønsteret brydes i dag, bare i det små til en begyndelse:-)

polle1

bibob a lula, wait and see, snart bliver det helt anderledes

bibob

Ja, jeg er heller ikke nervøs, men jeg tror først vi rykker efter en god guiding. Men nervøs ! ikke tale om

polle1

peter12

Så skal du sove 6 børsdage endnu

StockBull

Ser da meget godt. Lıdt posıtıv snak saa er der medvıng ıgen. TA ser ı mın lılle verden ogsaa ud som om de lange bukser saa smaat er ved at komme paa

bibob

Oh nooo. Bare jeg kan sove for spænding.

StockBull

Guıdıng naeste uge vıl kunne kıckstarte et breakout

StockBull

tror tıl gaengaeld guıdıng skal vaere meget daarlıg for at kursen skan under 900 ıgen

E_L

Transplant-Ineligible Myeloma: Daratumumab
. OncLiveTV - https://www.youtube.com/watch?v=fwbC9IUOo80

E_L

don't think it was posted yet?

E_L

Alcyone: After receiving 9 cycles of D-VMP, then just on Dara alone for maintenance; infection risk in the first 9 cycles; after that not many side effects; great strategy in this group of elderly patients
(-> Dara only is cheaper as well offcourse)

E_L

MAIA: for the elderly it is practice changing, SC future hightly convenient. Will be on-label very soon. “February 1st it will be standard therapy for me…”

Bulder

In think it is recorded before ash. But nevertheless they were all excited about dara. Fonseca: Maia curves much better than SWOG. I think he is exaggerating. Better but not much better.

Bulder

Important though in an elderly frail population: DRd seems milder than RVd.

JørgenVarnæs

er der nogen, der har tallene på tisotumab respons i cervical og bladder? Jeg tænker på N for population og patienter med respons

JørgenVarnæs

jeg kan ikke lige se de tal fra The Lancet - men kun responsraten for de 2 indikationer

E_L

does escalation 2 bladder, 2 cervical (from 27)

E_L

dose expansion 15 bladder 34 cervical (from 147)